Effect Of Nicotine on Neurocognitive Performance of Cigarette Smokers
This research project addresses the hypothesis that a neurocognitive profile characterized by impairment of response inhibition and sustained attention may be a risk factor for smoking initiation and nicotine dependence among young women. Nicotine has short- term, facilitating effects on attention and response inhibition. Therefore, individuals who are impaired on cognitive functions such as...
Brief Summary
Official Title: “Effect Of Nicotine on Neurocognitive Performance of Cigarette Smokers: A Double-Blind, Within-Subjects, Placebo-Controlled Study”
This research project addresses the hypothesis that a neurocognitive profile characterized by impairment of response inhibition and sustained attention may be a risk factor for smoking initiation and nicotine dependence among young women. Nicotine has short- term, facilitating effects on attention and response inhibition. Therefore, individuals who are impaired on cognitive functions such as these and initiate cigarette smoking may be more likely to maintain the habit and develop nicotine dependence. The research protocol specifically tests whether administration of nicotine to non-abstinent, regular cigarette smokers improves cognitive function in those domains where the participants had previously been shown to manifest performance deficits
- Study Type: Interventional
- Study Design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic
Intervention(s) in this Clinical Trial
- Drug: Nicotine
Outcome Measures for this Clinical Trial
Primary Measures
- Neurocognitive functions
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Reported smoking cigarettes on a daily basis at the time of the original study and continue to smoke currently
- Manifested poor performance on the MFFT (The neurocognitive test that yielded differences between smokers and non-smokers)
- Competent and willing to give written informed consent
Exclusion Criteria:
- Pregnancy, breast-feeding, non-use of contraception such that the possibility of pregnancy cannot be excluded
- Intake of any medication that may potentially interact with nicotine.
- Any current or past medical condition that represents a contra-indication to nicotine administration.
Gender Eligibility for this Clinical Trial: Female
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: 30 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: Accepts Healthy Volunteers
Clinical Trial Investigator Information
Lead Investigator: Hadassah Medical Organization Other
Overall Clinical Trial Officials and Contacts
Avi Yakir, MD Principal Investigator Hadassah Medical Organization
Overall Contact: Avi Yakir, MD 00 972 2 6777184 yakir@hadassah.org.il
Related Publications
Citations Reporting Results
Yakir A, Rigbi A, Kanyas K, Pollak Y, Kahana G, Karni O, Eitan R, Kertzman S, Lerer B. Why do young women smoke? III. Attention and impulsivity as neurocognitive predisposing factors. Eur Neuropsychopharmacol. 2006 Nov 29; [Epub ahead of print]
Additional Information
Information obtained from ClinicalTrials.gov on February 12, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00429208
Study ID Number: yakir@hmo
ClinicalTrials.gov Identifier: NCT00429208
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration
Biological Psychiatry Laboratory Hadassah- Hebrew University Medical Center, Jerusalem, Israel
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00429208
